Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16612394 | 0.98 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Methyl Alcohol SCHEMBL27463839 | 0.98 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL27893273 | 0.98 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL28133562 | 0.98 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Iodide SCHEMBL15174787 | 0.98 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL7858182 | 0.95 | HPGD (0.68) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL5053 | 0.95 | HPGD (0.68) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Acetic Acid SCHEMBL3768719 | 0.94 | USP2 (0.58) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL19852529 | 0.93 | HPGD (0.71) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL60470 | 0.93 | HPGD (0.71) | USP2SMN1; SMN2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1066 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634959-B1 | QUINOLINE DERIVATIVES FOR TREATING INFECTIONS WITH HELMINTHS | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-02-26 | — | — | EP | claimed |
| CN-119497712-A | Indane derivatives as MALT1 inhibitors | 希四克斯探索有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-113924146-B | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-119080663-A | Efficient low-cost synthesis method of azetidine hydrochloride | 南宁师范大学 | 2024-12-06 | — | — | CN | claimed |
| CN-118541362-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-08-23 | — | — | CN | claimed |
| CN-107531698-B | Fused bicyclic heteroaryl derivatives having activity as PHD inhibitors | 武田药品工业株式会社 | 2024-08-13 | — | — | CN | claimed |
| CN-111132977-B | Quinoline derivatives for the treatment of helminth infections | 礼蓝动物保健有限公司 | 2024-07-23 | — | — | CN | claimed |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | claimed |
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | claimed |
| WO-2024054944-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | JUNO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| CN-104140387-B | A kind of preparation method of N-tertbutyloxycarbonyl-azetidine aromatic ether/heteroaromatic ether compound | TETRANOV PHARMACY STOCK INC. (CN) | 2016-11-30 | — | — | CN | claimed |
| EP-1794129-B1 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-30 | — | — | EP | claimed |
| CN-104140387-A | Preparation method for N-tert-butyloxycarboryl-azetidine aromatic ether/aromatic heterocyclic ether compounds | TETRANOV BIOPHARM INC | 2014-11-12 | — | — | CN | claimed |
| CN-102264736-B | Substituted pyrazolo [1,5-a ] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC | 2013-08-14 | — | — | CN | claimed |
| CN-101883762-A | Benzothiazoles as modulators of growth hormone releasing hormone receptors | ASTRAZENECA AB | 2010-11-10 | — | — | CN | claimed |
| EP-1794129-A4 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-02 | — | — | EP | claimed |
| US-7402670-B2 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | claimed |
| EP-1794129-A2 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-13 | — | — | EP | claimed |
| WO-2006039383-A2 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | claimed |
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | DENG XIAOHU | 2006-03-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | SRM, SMOX, DDC | USP2 1919/4885SMN1; SMN2 3550/4885HPGD 2209/4885 |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | DGKG, DGKA, DGKI | USP2 3864/4885SMN1; SMN2 4303/4885HPGD 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.